SCD - Global Blood Therapeutics prices upsized $300M of notes offering

Global Blood Therapeutics (NASDAQ:GBT) has priced $300M of its 1.875% Convertible Senior Notes due 2028 in a private offering, upsized from previous offering size of $250M. Initial purchasers are granted an option to purchase up to an additional $45M of notes. Initial conversion rate is 31.4985 shares per $1,000 principal amount of notes (equivalent to ~$31.75/share). Net proceeds will be used to pay the cost of the capped call transactions, for development and commercialization of Oxbryta and other product candidates, and for other general corporate purposes. Closing date is December 17, 2021. Previously (Dec. 14): GBT slumps after announcing offering of $250.0M in convertible senior notes

For further details see:

Global Blood Therapeutics prices upsized $300M of notes offering